Trial reportDrug design, development and therapy2026
Modified Single-Side-Lying Quadratus Lumborum Block Combined with Liposomal Bupivacaine versus Transversus Abdominis Plane Block for Post-Cesarean Analgesia: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inadequate post-cesarean analgesia remains a common clinical issue, associated with increased opioid use and risks of chronic pain and postpartum depression. Although the anterior quadratus lumborum block (QLB III) is more effective than transversus abdominis plane (TAP) block, it requires repeated positioning and may cause quadriceps numbness. To address these limitations, we designed a modified QLB to overcome these drawbacks. This study evaluated its analgesic efficacy and safety when combined with liposomal bupivacaine in cesarean delivery. Methods: This single-center, randomized, single-blind trial enrolled 70 patients undergoing elective cesarean delivery. Patients were randomized to modified QLB (Group Q) or TAP block (Group T). The primary outcome was postoperative Day 1 VAS pain score. Secondary outcomes included VAS scores on Days 2, 3, during uterine compression and oxytocin infusion, opioid consumption, recovery metrics, and adverse events. Results: Baseline characteristics were well balanced between the two groups (all Conclusion: Modified single lateral decubitus QLB combined with liposomal bupivacaine yields superior analgesia and reduces opioid consumption compared with the TAP block, demonstrating favorable safety and clinical value for enhancing postoperative recovery following cesarean delivery. Nevertheless, these findings are limited by the single-center design and relatively small sample size, and long-term follow-up of chronic pain and postpartum mental outcomes was not performed. Trial Registration Number: ChiCTR2400094584. The trial is publicly available and is registered at https://www.chictr.org.cn on December 25, 2024.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.